AfaSci

AfaSci is a unique, self-sustaining biotech holding group with three synergistic business lines: therapeutic development (AfaSci Therapeutics), preclinical contract research services (AfaSci Research Laboratories), and research instrumentation (AfaSci Instruments). Its lead asset, AFA-281, is a Phase I-completed, novel dual-mechanism small molecule for chronic pain and epilepsy, protected by composition of matter patents in 16 countries. The company is currently seeking investment and partnerships to advance AFA-281 into Phase II proof-of-concept studies, with a potential exit via M&A upon successful trial results.

Proprietary phenotypic drug discovery platform supported by the SmartCage® automated rodent behavioral monitoring system and associated software for high-throughput in vivo evaluation. Focus on dual-mechanism small molecules targeting ion channels and inflammatory pathways.

AFA-281 competes in the crowded chronic pain space against other non-opioid analgesics, neuromodulators, and novel mechanism drugs, and in epilepsy against numerous anti-seizure medications. Its key proposed differentiation is its novel dual mechanism (ion channel + anti-inflammatory) as a single oral agent, aiming to offer efficacy without the risks of opioids or steroids.